TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
Signum Life Science AS
Closing information (x1000 NOK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
22,801
|
21,612
|
20,514 |
| Financial expenses |
116
|
120
|
76 |
| Earnings before taxes |
1,623
|
-477
|
32 |
| Total assets |
12,165
|
11,357
|
12,398 |
| Current assets |
8,612
|
6,825
|
8,013 |
| Current liabilities |
2,702
|
3,407
|
3,933 |
| Equity capital |
9,396
|
7,773
|
8,178 |
| - share capital |
2,000
|
2,000
|
2,000 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
77.2%
|
68.4%
|
66.0% |
| Turnover per employee | |||
| Profit as a percentage of turnover |
7.1%
|
-2.2%
|
0.2% |
| Return on assets (ROA) |
14.3%
|
-3.1%
|
0.9% |
| Current ratio |
318.7%
|
200.3%
|
203.7% |
| Return on equity (ROE) |
17.3%
|
-6.1%
|
0.4% |
| Change turnover |
1,189
|
1,098
|
-459 |
| Change turnover % |
6%
|
5%
|
-2% |
| Chg. No. of employees | |||
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.